Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in crohn's disease

Journal of Crohn's and Colitis

Volumn 9, Issue 11, 2015, Pages 1032-1042

  Steenholdt, Casper ^a   Brynskov, Jørn ^a   Thomsen, Ole O ^a   Munck, Lars K ^b   Christensen, Lisbet A ^c   Pedersen, Gitte ^d   Kjeldsen, Jens ^e   Ainsworth, Mark A ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KØGE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

activity; IBD; indirect costs; infliximab; loss of response; productivity; quality of life; work

Indexed keywords

BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; GASTROINTESTINAL AGENT;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE; ECONOMICS; FOLLOW UP; PROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE; WORK CAPACITY;

ABSENTEEISM; ADULT; CROHN DISEASE; EFFICIENCY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; LINEAR MODELS; MALE; PRESENTEEISM; PROSPECTIVE STUDIES; QUALITY OF LIFE; SINGLE-BLIND METHOD; TREATMENT FAILURE; WORK CAPACITY EVALUATION;

EID: 84963753584     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv139     Document Type: Article

References (40)

1. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001;96:2915-20.
2. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8
3. Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
4. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7
5. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59
6. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56
7. Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-Biroulet L. Clinical trials in ulcerative colitis: a historical perspective. J Crohns Colitis 2015;9:580-8
8. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.http://www.fda.gov/
9. Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 2003;125:982-4
10. Floyd DN, Langham S, Severac HC, Levesque BG. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci 2015;60:299-312
11. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55
12. Dignass A, Van AG, Lindsay JO, et al. The second European evidencebased Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62
13. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607
14. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212
15. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145:1459-63
16. Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. Inflamm Bowel Dis 2014;20:1242-9
17. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factoralpha antibodies. Scand J Gastroenterol 2009;44:774-81
18. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27
19. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in crohn's disease patients failing infliximab. Dig Dis Sci 2015;[Epub ahead of print]
20. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9
21. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654-66
22. Roblin X, Rinaudo M, Del TE, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250-6
23. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30
24. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32
25. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10
26. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8
27. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
28. Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404
29. van der Have M, Fidder HH, Leenders M, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis 2015;21:369-377
30. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009;104:1976-83
31. Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2015;41:77-86
32. van der Eijk I, Vlachonikolis IG, Munkholm P, et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis 2004;10:392-8
33. van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:93-106
34. Reilly MC, Brown M, Brabant Y, Gerlier L, Sandborn WJ. Defining the minimally important difference for WPAI:CD scores: what is a relevant impact on work productivity in active Crohn's disease? Gut 2007;56(Suppl III):A159
35. Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
36. Steenholdt C, Ainsworth MA. Authors' response: Importance of defining loss of response before therapeutic drug monitoring. Gut 2015;64:1340-1
37. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OE, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-64
38. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-4
39. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005;39:390-5
40. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65